Anthracycline associated cardiac toxicity in children with malignancies

Indian Pediatrics

Volumn 39, Issue 6, 2002, Pages 549-555

  Mohta, R ^a   Saxena, A ^a   Jain, Y ^a   Gupta, S ^a   Thavaraj, V ^a   Narain, Sunil ^a   Arya, L S ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DAUNORUBICIN; DOXORUBICIN;

ACUTE LYMPHOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CHILD; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; ECHOCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HEART INDEX; HUMAN; MALE; NEUROBLASTOMA; NUTRITIONAL STATUS; RETINOBLASTOMA;

ANTIBIOTICS, ANTINEOPLASTIC; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART; HEART DISEASES; HEART FUNCTION TESTS; HEMODYNAMIC PROCESSES; HUMANS; INCIDENCE; INFANT; MALE; MONITORING, PHYSIOLOGIC; NEOPLASMS; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 0036084306     PISSN: 00196061     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Blum RH, Carter SK. Adriamycin: A new anticancer drug with significant clinical activity. Ann Intern Med 1974; 80:249-259.
2. Lenaz L, Page GA. Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat Rev 1976; 3:111-120.
3. Praga C, Besetta PL, Vigo BR. Adriamycin cardiotoxicity: A survey of 1273 patients. Cancer Treat Rep 1979; 63:827-834.
4. Pratt CB, Ransom JL, Evans WE. Age related adriamycin cardiotoxicity in children. Cancer Treat Rep 1978; 62:1381-1385.
5. Von Hoff DD, layard M, Basa P. Risk factors for doxorubicin induced congestive heart failure. Ann Intern Med 1979; 91:710-717.
6. Siblber JH, Jackacki RI, Larsen RI, Goldwein JW, Barber G. Increased risk of cardiac dysfunction after anthracyclines in girls. Med Pediatr Oncol 1993; 21:477-479.
7. Ohama M, Cangir A, Eyes JV. Nutritional status and anthracycline cardiotoxicity in children. South Med J 1983; 76:577-578.
8. Lim BL, Svec JM, Torti FM. Doxorubicin: Alteration of dose scheduling as a means of reducing cardiotoxicity. Drug intell Clin Pharm 1985; 19:259-264.
9. Bristow MR, Mason JW, Billingham ME, Daniels JR. Doxorubicin cardiomyopathy: Evaluation by phonocardiography, endomyocardial biopsy and cardiac catheterisation. Ann Intern Med 1978; 88:168-175.
10. Steinherz LJ, Steinherz P. Cardiac failure more than 6 years post anthracycline therapy. Am J Cardiol 1988; 62:505.
11. Steinherz LJ, Graham T, Hurwitz R, Sondheimer HM, Schwartz RG, Shaffer EM, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: Report of the cardiology committee of the children cancer study group. Pediatrics 1992; 89:942-949.
12. Aggarwal DK, Aggarwal KN, Upadhyay S, Mittal R, Prakash R, Rai S. Data from physical and sexual growth of affluent Indian children. Indian Pediatr 1992; 29:1203-1284.
13. Goorin AM, Borow KM, Goldman A, Williams RG, Henderson IC, Sallan SE et al. Congestive heart failure due to adriamycin cardiotoxicity: Its natural history in children. Cancer 1981; 47: 2810-2816.
14. Vick JA, Garattini S, Dohneli MG, De Felici SL, Sanzari NP. Prevention of adriamycin induced toxicity with carnitine. Physiologist 1975; 5:221-224.
15. Ferrans VJ. Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat Rep 1978; 62:955-961.
16. Sonneveld P. Effect of alpha tocopherol on the cardiotoxicity of adriamycin in the rat. Cancer Treat Rep 1978; 62:1033-1036.
17. Ali MK, Soto A, Maroongroge D, Saad SB, Buzdar AU, Blumenschein GR, et al. Electrocardiographic changes after adriamycin chemotherapy. Cancer 1979; 43:465-471.
18. Bloom KR, Williams CM, Sonley MJ, Gribbin MA. Echocardiography in adriamycin cardiotoxicity. Cancer 1978; 41:1265-1269.